Vogt-Koyanagi-Harada Disease: The Clinical Spectrum and Management of Case Series in a Tertiary Eye Centre in Northern Part Of Malaysia
Authors:
Atiqah Nur Hasan 1,2; Mushawiahti Mustapha 2; Haslina Abdul Halim Wan Wan 2
Authors‘ workplace:
Department of Ophthalmology, Hospital Sultanah Bahiyah, Malaysia
1; Department of Ophthalmology, Faculty of Medicine, University, Kebangsaan Malaysia Medical Center, Malaysia
2
Published in:
Čes. a slov. Oftal., 80, 2024, No. 3, p. 140-144
Category:
Original Article
doi:
https://doi.org/10.31348/2024/1
Overview
Aims: We present the clinical spectrum, the initial clinical presentation with management trends in treating 14 Vogt-Koyanagi-Harada (VKH) disease cases in a tertiary center in the Northern part of Malaysia.
Case series: There were 14 cases of Vogt-Koyanagi-Harada (VKH) disease retrospectively reviewed over five years (from 2015 to 2020). The mean age at presentation was 37.7 years (range 21–64 years), with female predominance (85.7%). All cases presented with acute uveitic stage and bilateral eye involvement. Of them, 11 (78.6%) were probable VKH, and three (21.4%) were incomplete VKH. All patients attended with acute panuveitis at first presentation. The main posterior segment involvement was disc edema in 57.1% (16 out of 28 eyes) and exudative retinal detachment (ERD) in 35.7% (10 out of 28 eyes). Most of them presented with blindness (3/60 and worse) and moderate visual impairment (6/18–6/60); 35.71% each, followed by mild visual impairment (6/12–6/18), and severe visual impairment (6/60–3/60); 7.1% each. Ten patients (71.4%) required combination second-line immunomodulatory treatment during subsequent visits, and only four patients (28.6%) responded well to corticosteroid therapy. Most of the cases achieved no visual impairment (64.3%), followed by mild visual impairment (21.4%) and moderate visual impairment (14.3%), and none were severe or blind at the end of follow-up.
Conclusion: VKH is a potentially blinding illness if there is inadequate control of the disease in the acute stage. Most of our patients achieved good visual outcomes with early immunomodulatory treatment and systemic corticosteroids.
Keywords:
corticosteroid – Vogt-Koyanagi-Harada Disease – immunomodulatory – panuveitis
Sources
1. Lodhi SAK, Lokabhi, RJM, Peram V. Clinical spectrum and management option in Vogt-Koyanagi-Harada disease. Clin Ophthalol. 2017;11:1399-1406.
2. Kharel R, Shah DN, Chaudhary M. Presumed Vogt-Koyanagi-Harada (VKH) disease in Nepalese population; a rare entity. Clini Ophthalmol Res.2016;4:97-100.
3. Agrawal A, Biswas J. Unilateral Vogt-Koyanagi-harada disease, report of two cases. Mid E Afr J Ophthalmol. 2011;8:82-84.
4. Usui Y, Goto H, Sakai H, Takeuchi M, Usui M, Rao NA. Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases. Graef Arch Clin Exp Ophthalmol. 2009;247:1127-1132.
5. Pranav S, Sadhana S, Ranju K. Vogt-Koyanagi-Harada Disease: A case Series in a Tertiary Eye Centre. Hind Case Rep Ophthalmol Med. 2021.doi 10.1155/2023/8848659
6. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Opthalmol.1994;78(3):223-226.
7. Shindo Y, Ohno S, Yamamoto T, Nakamura S, Inoko H. Complete association of HLA-DRB1*04 and-DQB1*04 alleles with Vogt-Koyanagi-Harada’s disease. Hum Immunol.1994;39(3):169-176.
8. Samy AM, Ngah NF, Khialdin SM, Azli NA, Hussin NH, Anee A. Association between HLA-DRB1*04 and Malay patient with Vogt-Koyanagi-Harada syndrome in Malaysia: A case control study. Malaysian Journal of Ophthalmology.2019;2:84-97. doi 10.35119/MYJO.V112.11
9. Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432-435. doi 10.1007/s10384-012-0158-z
10. Oo EEL, Chee SP, Yan Wong KK, Htoon HM. Vogt-Koyanagi-Harada Disease managed with Immunomudulatory Therapy within 3 months of disease onset. Am J Opthalmol. 2020. 12. 1991
11. Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87-90.
12. Deák G, Koreishi AF, Goldstein DA. Do not discount the diagnosis of VKH based on race: self-reported race and ethnicity of patients with Vogt-Koyanagi-Harada disease in a predominantly white population. J Ophthalmic Inflamm Infect 2023 Mar 29. https://doi.org/10.1186/s12348-023-00329-2
13. Diallo K, Revuz S, Clavel-Refregiers G et al. Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients. BMC ophthalmology. 2020;20. 395. https://doi.org/10.1186/s12886-020-01656-x
14. Katsuyama A, Kusuhara S, Awano H, Nagase H, Matsumiya W, Nakamura M. A case of probable Vogt-Koyanagi-harada disease in a 3-year-old girl. BMC ophthalmology. 2019 (19):179. https://doi.org/10.1186/s12886-019-1192-0
15. Zhong Z, Dai L, Wu Q, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressents versus biologics for Vogt-Koyanagi-Harada disease. 1 komunikace. 2023. června 2017 3768.
16. Chee SP, Jap A, Bacsal C. Spectrum of Vogt–Koyanagi–Harada disease in Singapore. Jpn J Ophthalmol. 2009;27:137-142. doi 10.1007/s10792-006-9009-6
17. Herbort Jr, Abu El Asrar A, Takeuchi M. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease. Jpn J Ophthalmol. 2019;39:1419-1425.
18. Read RW, Holland GN, Rao NA et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease; repot of an international committee on nomenclature. Am J Opthalmol. 2001;131(5):647-652.
19. International Classification of Disease-11 for Mortality and Morbidity-2018 [Internet]. Available from:http://id.who.int/icd/entity/1103667651
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2024 Issue 3
Most read in this issue
- Radiation Maculopathy in Patients with Malignant Melanoma of the Corpus Ciliare and Choroidea Following One-Day Session of Stereotactic Radiosurgery
- Visual Neuroprosthesis – Stimulation of Visual Cortical Centers in The Brain. Design of Non-Invasive Transcranial Stimulation of Functional Neurons
- Evaluation of Clinical Results of Implantation of Toric Intraocular Lenses Including their Rotational Stability
- Therapy for Vitreous Seeding Caused by Retinoblastoma. A Review